MA50972A - Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide - Google Patents
Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamideInfo
- Publication number
- MA50972A MA50972A MA050972A MA50972A MA50972A MA 50972 A MA50972 A MA 50972A MA 050972 A MA050972 A MA 050972A MA 50972 A MA50972 A MA 50972A MA 50972 A MA50972 A MA 50972A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
- LSYANGLAZUZYFX-UHFFFAOYSA-N N-[1-[(5-cyanopyridin-2-yl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide Chemical compound C(#N)C=1C=CC(=NC=1)CN1N=C(C=C1)NC(CC1=CC=C(C=C1)C1(CC1)C(F)(F)F)=O LSYANGLAZUZYFX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50972A true MA50972A (fr) | 2020-10-14 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050972A MA50972A (fr) | 2017-07-05 | 2018-07-04 | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (fr) |
| EP (1) | EP3649117A1 (fr) |
| JP (2) | JP2020525475A (fr) |
| KR (1) | KR102645911B1 (fr) |
| CN (1) | CN110831932A (fr) |
| AU (1) | AU2018296423B2 (fr) |
| BR (1) | BR112020000099A2 (fr) |
| CA (1) | CA3067489A1 (fr) |
| CL (1) | CL2020000002A1 (fr) |
| EA (1) | EA202090193A1 (fr) |
| IL (1) | IL271764B2 (fr) |
| MA (1) | MA50972A (fr) |
| PH (1) | PH12020500040A1 (fr) |
| SG (1) | SG11201912881SA (fr) |
| UA (1) | UA126582C2 (fr) |
| WO (1) | WO2019008034A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201991428A1 (ru) | 2016-12-16 | 2019-12-30 | Идорсия Фармасьютиклз Лтд | Фармацевтическая комбинация, содержащая блокатор кальциевых каналов т-типа |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| JP2020525475A (ja) * | 2017-07-05 | 2020-08-27 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形 |
| US20230047102A1 (en) | 2019-12-20 | 2023-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| WO2023240205A1 (fr) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Composés deutérés |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100712A1 (es) | 2014-06-03 | 2016-10-26 | Actelion Pharmaceuticals Ltd | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t |
| KR102424750B1 (ko) | 2014-09-15 | 2022-07-22 | 이도르시아 파마슈티컬스 리미티드 | T-형 칼슘 채널 차단제로서의 트리아졸 화합물 |
| EA201991428A1 (ru) | 2016-12-16 | 2019-12-30 | Идорсия Фармасьютиклз Лтд | Фармацевтическая комбинация, содержащая блокатор кальциевых каналов т-типа |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| JP2020525475A (ja) * | 2017-07-05 | 2020-08-27 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形 |
-
2018
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 EP EP18749304.4A patent/EP3649117A1/fr active Pending
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active IP Right Grant
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/fr unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/fr active Pending
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110831932A (zh) | 2020-02-21 |
| AU2018296423A1 (en) | 2020-02-20 |
| AU2018296423B2 (en) | 2022-07-28 |
| JP2023123679A (ja) | 2023-09-05 |
| BR112020000099A2 (pt) | 2020-07-07 |
| EA202090193A1 (ru) | 2020-06-03 |
| EP3649117A1 (fr) | 2020-05-13 |
| US20200165221A1 (en) | 2020-05-28 |
| UA126582C2 (uk) | 2022-11-02 |
| IL271764B2 (en) | 2023-10-01 |
| WO2019008034A1 (fr) | 2019-01-10 |
| KR20200018698A (ko) | 2020-02-19 |
| IL271764B1 (en) | 2023-06-01 |
| US20210300894A1 (en) | 2021-09-30 |
| PH12020500040A1 (en) | 2020-10-12 |
| CL2020000002A1 (es) | 2020-07-31 |
| KR102645911B1 (ko) | 2024-03-08 |
| US11555025B2 (en) | 2023-01-17 |
| IL271764A (en) | 2020-02-27 |
| CA3067489A1 (fr) | 2019-01-10 |
| JP2020525475A (ja) | 2020-08-27 |
| SG11201912881SA (en) | 2020-01-30 |
| US11059803B2 (en) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50972A (fr) | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide | |
| IL266214B (en) | 5,4,2-tri-converted 4,2,1-triazolones used as dhodh inhibitors | |
| IL274488A (en) | Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| MA51066A (fr) | Inhibiteurs d'intégrine | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| IL271726A (en) | Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2, 6-doxopyridin-3-yl)-1-oxoisoinodolin-5-yl)methyl)2-2-difluoroacetamide | |
| HK1259405A1 (zh) | N-[5-(3，5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
| SI3464265T1 (sl) | Polimorfi N-((3-fluoro-4-metoksipiridin-2-IL)metil)-3-(metoksimetil)- 1-((4-(2-oksopiridin-1-IL)metil)fenil)pirazol-4-karboksamida kot zaviralci kalikreina | |
| MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
| ZA201804482B (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| DK3395342T3 (da) | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf | |
| EP3263553A4 (fr) | Modification cristalline de n-(2- (3-phényluréido)phényl)-benzènesulfonamide et matériau d'enregistrement l'utilisant | |
| DK3255046T3 (da) | Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf | |
| GB2571937B (en) | Stable liquid suspension composition of fludrocortisone | |
| IL284509A (en) | Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide | |
| FR3035318B1 (fr) | Materiel d'osteosynthese vertebrale | |
| SG11202103847QA (en) | Estimation of asymmetric aberrations | |
| FR3035584B1 (fr) | Materiel d'osteosynthese vertebrale | |
| PT3643704T (pt) | Novos intermediários para a preparação de hidrocloreto de remifentanil | |
| IT201700025286A1 (it) | Forme cristalline di vinpocetina cloridrato | |
| GB201621528D0 (en) | Use of trpv1 agonist |